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https://doi.org/10.1016/j.celrep.2020.107711SUMMARYThe availability of an autologous transplantable auxiliary liver would dramatically affect the treatment of liver
disease. Assembly and function in vivo of a bioengineered human liver derived from induced pluripotent stem
cells (iPSCs) has not been previously described. By improving methods for liver decellularization, recellula-
rization, and differentiation of different liver cellular lineages of human iPSCs in an organ-like environment, we
generated functional engineered human mini livers and performed transplantation in a rat model. Whereas
previous studies recellularized liver scaffolds largely with rodent hepatocytes, we repopulated not only the
parenchyma with human iPSC-hepatocytes but also the vascular system with human iPS-endothelial cells,
and the bile duct network with human iPSC-biliary epithelial cells. The regenerated human iPSC-derived
mini liver containing multiple cell types was tested in vivo and remained functional for 4 days after auxiliary
liver transplantation in immunocompromised, engineered (IL2rg/) rats.INTRODUCTION
Approximately 30 million people in the USA have liver disorders,
and about 40,000 of them will progress to end-stage liver dis-
ease, which is responsible for >30,000 deaths annually in the
USA (HHS HRSA, 2014; Habka et al., 2015) The only curative
treatment for patients with terminal liver failure is liver transplan-
tation. The shortage of donor livers, the high cost of the proced-
ure, and the requirement for lifelong immunosuppression are
limits to its application (Ammori et al., 2008). Autologous bio-
engineered livers derived from the patient’s own cells couldThis is an open access article under the CC BY-Nchange this equation by providing unlimited availability of grafts
whose use would not require the need for immunosuppression.
To this end, induced pluripotent stem cells (iPSCs) are a valuable
autologous cell source that can establish various types of tissue
lineages (Takahashi et al., 2007). We (Collin de l’Hortet et al.,
2019; Soto-Gutiérrez et al., 2011b; Uygun et al., 2010; Yagi
et al., 2013) and others (Baptista et al., 2011; Butter et al.,
2018; Hassanein et al., 2017; Kojima et al., 2018; Zhou et al.,
2016) have engineered liver grafts by infusing hepatocytes and
endothelial cells into the liver parenchymal and vascular com-
partments using rat liver cells, human cell lines, and human fetalCell Reports 31, 107711, June 2, 2020 ª 2020 The Author(s). 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(legend on next page)






OPEN ACCESSliver cells. Several liver decellularization and recellularization
strategies have been described in the literature (Mazza et al.,
2015; Ko et al., 2015; Kojima et al., 2018; Zhou et al., 2016),
but only limited graft function has been reported using primary
cell sources. Recently, we reported the generation of liver grafts
using genetically engineered human iPSCs differentiated into
liver cells, together with supporting primary human cells tomimic
many aspects of human fatty liver disease (Collin de l’Hortet
et al., 2019). However, bioengineering of an entire liver graft us-
ing human iPSC-derived cells for transplantation has not been
described.
It is important to note that complete reestablishment of the
liver microarchitecture would require efficient repopulation of
the vasculature with endothelial cells. Long-term engraftment
of any engineered organ will require a functioning vascular
network to provide oxygen and nutrients. The main limitation of
bioengineered liver constructs to date is that sparse, or no endo-
thelial cell repopulation of the vasculature, makes them highly
susceptible to thrombosis (Bao et al., 2011; Ko et al., 2015; Uy-
gun et al., 2010). Moreover, the incorporation of additional cell
types in the bioengineered liver, such as biliary epithelial cells,
which would drain bile and remove waste-metabolized products
(Beath, 2003), has not been reported, to our knowledge.
In this study, we developed protocols for hepatocyte-, cholan-
giocyte-, and endothelial-cell differentiation of human iPSCs
(Chen et al., 2018). Hepatocyte differentiation was achieved in
a low-glucose environment by delivering metabolic and energy
maturation cues that included hepatocyte growth factor (HGF),
epidermal growth factor (EGF), dexamethasone, hydrocortisone,
free fatty acids, cholesterol, bile acids, and rifampicin. Human
iPSC-derived hepatocytes (iPSC-Heps) expressed liver-en-
riched transcription factors and liver-specific microRNAs (miR-
NAs), and contained mitochondria at levels found in freshly
isolated primary human hepatocytes.
Human iPSCs were also differentiated into cholangiocytes
that expressed markers found in mature bile ducts, such as cy-
tokeratin 7 (CK7), CK19, SRY-BOX 9 (SOX9), hepatic nuclear
factor 1 beta (HNF1b), and cystic fibrosis transmembrane
conductance regulator (CFTR). Human iPSC-derived vascular
endothelial cells (hiPSC-VECs) engrafted themselves in a decel-
lularized rat liver vascular structure and showed an enhanced
expression of angiogenesis and anticoagulation-related genes
and functions in the organ-like environment. Finally, we seeded
liver scaffolds with human iPSC-derived hepatocytes, endothe-
lial cells, and cholangiocytes, and human primary-liver-derivedFigure 1. Generation of Hepatocytes from Human-Induced Pluripotent
(A) Schematic representation of the protocol used to differentiate human iPSCs to
HGF, hepatocyte growth factor; DMSO, dimethyl sulfoxide; EGF, epidermal grow
hydrocortisone; Chol, cholesterol.
(B) Light microscopy images (top) of human iPSC-derived cells at day 4, day 14
strating the expression of key definitive endoderm and hepatocyte markers, as in
adult isoform of hepatocyte nuclear factor 4a (HNF4a), alpha-fetoprotein (AFP), an
also shown. iPSCs-Heps, iPSC-derived hepatocytes; iPSC-DE, iPSC-derived de
(C) Liver-specific gene expression profile.
(D) MicroRNA-122 (miRNA122), -148a, and -194 of human iPSC-derived hepato
fetal hepatocytes (HFHs; gestational age: weeks 20–22). Data are expressed as th
controls in all experiments. Results are representative of three independent diffe
Heps at days 14 and 28: *p < 0.05. Error bars represent mean ± SD of three indefibroblast and mesenchymal stem cells, to mimic the liver
microstructure. We achieved liver vasculature coverage of
75% and bile-duct coverage of 66% of that observed in normal
liver using human iPSC-derived cells. The liver parenchymal
cells in engineered iPSC liver grafts expressed cell-cell and
cell-extracellular matrix (ECM) molecules and function at levels
found in human adult and fetal livers or engineered liver grafts
assembled with primary liver cells or in 3D cultures containing
freshly isolated primary human fetal and adult hepatocytes. Af-
ter auxiliary transplantation of human iPSC-derived bio-
engineered livers in engineered immunocompromised (inter-
leukin [IL] 2rg/) rats conditioned to induce liver regeneration,
the grafts functioned for four days.
RESULTS
Differentiation of Human iPSCs into Hepatocytes
To induce differentiation of human iPSCs toward a hepatocyte
phenotype (iPSC-Heps), we used our previously published proto-
col (Basma et al., 2009; Soto-Gutiérrez et al., 2006, 2007b) with
modification of the endoderm induction steps (stages 1 and 2)
so that cells were cultured in monolayers for four days rather
than as three-dimensional (3D) embryoid bodies (Figure 1A).
More than 90% of the resulting cells expressed the definitive
endoderm markers SOX17 (Figure 1B) and CXC chemokine re-
ceptor 4 (CXCR4; Figure 1C) at day 4 using activin A, bone
morphogenetic protein 4 (BMP4), and fibroblast growth factor
(FGF)-2. For hepatic maturation, cells were cultured for 14 days
in the presence of dimethyl sulfoxide (DMSO) and HGF and, for
the last four days, cells were cultured in low glucose in the pres-
ence of EGF, dexamethasone, hydrocortisone, free fatty acids,
bile acids, cholesterol, and rifampicin (Figure 1A). By day 14 of dif-
ferentiation (stage 3), after treatment with HGF and DMSO,
approximately 70% of cells expressed the adult isoform of
HNF4a and albumin, but cells did not express alpha-fetoprotein
(AFP; an immature hepatocytemarker; Figure 1B). mRNA analysis
of HGF and DMSO-treated cells (stage 3) showed upregulation of
liver-enriched transcription factors FOXA1, FOXA2, HNF4a,
HNF1a, CCAAT enhancer binding protein alpha (CEBPa), peroxi-
some proliferator-activated receptor alpha (PPARa), liver X recep-
tor (LXR), and retinoid X receptor (RXR; Figure 1C), and liver spe-
cific-microRNAs miR122 (Bandiera et al., 2015), miR148a (Heo
et al., 2018), and miR194 (Morimoto et al., 2017; essential for he-
patocyte function and homeostasis) to levels approximating those
for human fetal and adult hepatocytes.Stem Cells (iPSCs)
hepatocytes. BMP, bonemorphogenetic protein; FGF, fibroblast growth factor;
th factor; DEX, dexamethasone; FFA, free fatty acids; RIF, rifampicin; Hydro,
, and day 18 of hepatic differentiation. Immunofluorescence analyses demon-
dicated, in day 4, day 14, and day 18 using antibodies that recognized SOX17,
d albumin (ALB). Bar graphs showing the levels of positive cell percentage are
finitive endoderm; DAPI, 40,6-diamidino-2-phenylindole dihydrochloride.
cytes (iPSC-Heps) compared to human adult hepatocytes (HAHs) and human
e fold change relative to HAHs, which is set as 1. HAHs and HFH were used as
rentiation experiments. ANOVA with Wilcoxon test compared between iPSC-
pendent experiments.
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OPEN ACCESSFull human livermaturation takes as long as two years from the
time of birth (Chen et al., 2018), and is affected by changes in cir-
culation, microbiome, and nutrition (Chen et al., 2018). The liver
initially processes nutrients received from maternal blood in
utero, and later absorbs maternal milk in the intestines (Beath,
2003; Chen et al., 2018). In preliminary experiments, we analyzed
the alterations in the gene-expression patterns using microar-
rays to determine the effects of the maturation process in human
liver and the differences between fetal hepatic state and a fully
matured adult human liver (Mendeley data: https://doi.org/10.
17632/ncxxgwdwty.1). Clustering and a heatmap revealed that
fetal liver samples had a similar expressing pattern to each other,
but was significantly different from that of adult samples (Fig-
ure S2A). Genes involved in cell-cycle and cell-proliferation path-
ways showed significantly higher expression in fetal liver when
compared to adult liver (Figure S2B). In contrast, genes signifi-
cantly overexpressed in adult liver were metabolic-related
genes, including three major functional groups; fatty acid meta-
bolism-, xenobiotic metabolism-, and glucose metabolism-
related pathways (Figures S2B and S2C).
To mimic these metabolic changes, we examine the effect of
using media with a low glucose concentration, and adding free
fatty acids (palmitic and oleic acid), bile acids (ursodeoxycholic
acid), cholesterol, corticoids (dexamethasone and hydrocorti-
sone), EGF, and rifampicin to the culture to promote further he-
patocytematuration of human iPSCs. By day 18 of differentiation
(stage 4), approximately 75% of cells expressed the adult iso-
form of HNF4a and nearly 100% expressed albumin with no
expression of AFP expression (Figure 1B). Maturation in the
above components increased the expression of genes encoding
insulin-signaling/lipogenesis and mature, clinically relevant en-
zymes such as LXR, C-MET, ATP-binding cassette transporter
A1 (ABCA1), alpha-1-antitrypsin (A1AT), uridine diphosphate
glucuronosyltransferase 1 A1 (UGTA1), and FAH. We also found
a significant increase in the expression of miR148a and miR194
(Figure 1C).
There was a dramatic change inmorphology during the course
of the differentiation process. Transmission electron microscopy
revealed cells with mature round nuclei, evenly distributed chro-
matin, Golgi complexes, abundant mitochondria with clear
membranes, and well-developed bile canaliculi with apical
microvilli and tight junctions (Figure 2A). These findings were
confirmed using three independent human iPSC lines (Figures
S4A–S4D; Figures 2A–2C). As mitochondria are the main energy
producer in hepatocytes and play a central role in oxidative
metabolism, function, and replication (Yamashina et al., 2009),
we examined the mitochondria using the stain MitoTracker and
found that there was no quantitative difference in mitochondrial
numbers between human iPSC-Heps and control human fetal
and adult hepatocytes (Figures 2A–2C), and that human iPSC-
Heps (day 18) expressed levels of mitochondrial DNA similar to
the levels found in human adult hepatocytes (Figure 2D).
There was also no difference in intracellular triglyceride con-
tent (Figure 2E) between the groups, and human iPSC-Heps
propagated in culture at a rate similar to that of human fetal
hepatocytes during the maturation phase (stage 4; Figure 2F).
Human iPSC-Heps at day 18 (stage 4) accumulated glycogen
(Figure 2G) and produced significantly higher amounts of urea4 Cell Reports 31, 107711, June 2, 2020than did human iPSC-Heps at day 14 (stage 3), and 15%–20%
of that produced by freshly isolated human fetal and adult hepa-
tocytes (Figure 2H). The amount of human A1AT secreted into
the medium was similar to that generated by human primary he-
patocyte controls. As expected, the human-hepatocyte-specific
cytochrome P450 activity (CYP3A4) in human iPSC-Heps at day
18 (D18) after exposure to rifampicin was at the level of human
fetal hepatocytes (0.85-fold and 1.44-fold induction) and inferior
to that observed in adult human hepatocytes (8.38-fold induc-
tion; Figure 2H).
Differentiation of Human iPSCs into Cholangiocytes and
Assembly of Whole-Liver Human Bile Ducts
To generate hepatoblasts, day-4 (stages 1 and 2) definitive
endoderm cells were exposed to BMP4 and FGF2 (stage 3) for
five days (Dianat et al., 2014; Gouon-Evans et al., 2006; Ogawa
et al., 2013). To further differentiate hepatoblasts into cholangio-
cyte progenitors, cells were exposed to Activin A, FGF-10, and
retinoic acid for four more days (Sampaziotis et al., 2015; stage
4). mRNA expression for markers of early biliary specification,
SOX9, HNF1b, and CFTR, was upregulated (Figure 3B), and
CK7 and AFP were detected (Figure 3B), indicating a transition
into cholangiocyte progenitors. As Notch and transforming-
growth-factor beta (TGFb) signaling pathways are considered
regulators of biliary commitment of hepatoblasts (Flynn et al.,
2004; Ogawa et al., 2015; Sampaziotis et al., 2015; Clotman
et al., 2005; Schaub et al., 2018), we added (stage 5) EGF, Inter-
leukin-6 (IL6), dexamethasone, sodium pyruvate, TGFb1, and
sDLL-1 (ligand for Notch receptors) to the differentiation pro-
gram. Following this treatment, the cells expressed CK7 (88%),
CK19 (94%), and SOX9 (74%), and AFP expression was lost.
mRNA expression of CFTR (p = 0.037, n = 3) and inositol
1,4,5-trisphosphate receptor, type 3 (ITPR3; p < 0.001, n = 3)
significantly increased to levels comparable to those in human
extrahepatic bile duct (HEHBD) controls, and hepatocyte
markers HNF4, LXR, and UGT1A1 became absent or were
severely reduced (Figure 3B), indicating differentiation into cells
resembling biliary epithelial cells. Next, to characterize the func-
tionality of the generated human iPSC-cholangiocytes, we used
three-dimensional (3D) culture conditions through organoid for-
mation for the last maturation stage 5, and evaluated the capac-
ity of human iPSC-cholangiocyte-derived organoids for active
export of bile acids (Figure 3C); it showed that human iPSC-chol-
angiocyte-derived organoids actively export fluorescent-bile-
acid cholyl-lysyl-fluorescein (CLF) from the lumen of CLF-loaded
organoids compared to controls loaded with fluorescein isothio-
cyanate (FITC; Figure 3C).
We next decellularized rat livers, as described in Liver Procure-
ment andDecellularization.Wepreviously showed that decellular-
ized livers preserved vascular and biliary structure (Soto-Gutiérrez
et al., 2011b; Uygun et al., 2010; Yagi et al., 2013).We studied and
optimized recellularization of the bile duct by perfusing the labeled
human-cholangiocyte cell line (MMNK-1) through the biliary struc-
ture. Repopulation was assessed at the level of the whole liver us-
ing micro-computed tomography (CT) and micro-magnetic reso-
nance imaging (MRI; Figure 3D). Using micro-MRI, each liver
lobe was evaluated at different depths and we compared the re-
sults seen to a normal biliary system (Masyuk et al., 2001) using
Figure 2. Characterization of Human iPSC-Heps
(A) Transmission electron microscopy (TEM) images for cell organelles (upper), bile canaliculi with apical microvilli and tight junctions (middle), and mitochondria
(lower).
(B–D) Immunofluorescence analyses demonstrating the mitochondria staining using the stain MitoTracker. Graphs showing (C) the number of mitochondria
determined by counting the mitochondria described in TEM, (D) the amount of mitochondria DNA (mtDNA) by PCR, and (E) the amount of triglyceride in the cells.
(F) Cell-number curve of human iPSC-Heps, HFHs (gestational age; weeks 22–23), and HAHs during in vitro culture determined by the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
(G) Human iPSC-Heps, as well as HFH and HAHs showed glycogen storage by PAS (periodic acid-Schiff) staining.
(H) Urea and human alpha1 antitrypsin (A1AT) production by human iPSC-Heps was analyzed after in the culture medium by enzyme-linked immunosorbent
assay (ELISA). Human-adult CYP450 activity is also shown expressed in fold induction. Results are representative of three independent differentiation experi-
ments. ANOVA with Wilcoxon test compared between human iPSC-Heps at day 14 and day 18: *p < 0.05. Error bars represent mean ± SD of three independent
experiments. HFH and HAHs were used as the control in all experiments.
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OPEN ACCESSmicro-CT images, since all cholangiocytes in a normal liver cannot
be visualized by micro-MRI (Figures S5A and S5B). The best
seeding protocol repopulated 59% ± 24% (n = 5) of the bile ducts
relative to those of the native rat liver, as evaluated bymicro-imag-
ing (Figure 3D; Masyuk et al., 2001), and confocal microscopy
demonstrated a branched, tree-like bile canalicular network in
all segments of the liver (Figure S5D). Quantitative histological
scoring analysis of individual bile ducts showed bile-duct epithe-
lial cell lining on the interior of the bile-duct walls at 70% ± 18%
(n=7) as compared to that found in the native rat liver (FigureS5D).We therefore seeded human iPSC-derived cholangiocytes
through the biliary structure of the decellularized liver using the
best protocol, consisting of three 2-million cell infusions at 15-
min intervals and resulting in the highest level of bile-duct repopu-
lation, with human iPSC-derived cholangiocytes lining 65% ± 8%
(n = 3) of the interior bile duct wall (Figure 3E). Furthermore, after
two days of bile-duct repopulation process, iPSC-derived cholan-
giocytes in regenerated bile-duct grafts continued to express
cholangiocyte-specific markers, such as CK7 and CK19
(Figure 3E).Cell Reports 31, 107711, June 2, 2020 5
(legend on next page)






OPEN ACCESSCharacterization of hiPSC-VECs and Assembly of
Whole-Liver Human Vasculature
We then studied the changes that hiPSC-VECs undergo as a
result of changing from 2D culture to an organ-like culture in a
perfused vascular lumen (Jang et al., 2019; Ren et al., 2015).
hiPSC-VECs expressed CD31 (83% ± 2%), eNOS (endothelial
nitric oxide synthase) (76% ± 3%), and von Willebrand factor
(vWF; 34% ± 2%), compared to the expression of CD31 (95%
± 1%), eNOS (83% ± 2%), and vWF (93% ± 1%) in control human
neonatal microvascular endothelial cells (hNMVECs; Figure 4A)
when cultured for five passages in a 2D format.
To assemble the liver vasculature, we repopulated decellular-
ized livers through the portal and central vein structures with a
recirculation system. To optimize endothelial coverage, we
tested different cell concentrations and seeding flow rates.
Initially a labeled human liver endothelial cell line (TMNK-1;
Soto-Gutiérrez et al., 2006) was used for optimization studies
and then hiPSC-VECs or hNMVECs were used for all studies
(Figure S5A). We found that the best endothelial coverage of
the vascular system was accomplished when cell seeding was
performed through both the vena cava and then the portal
vein, with an interval of 6 h with no perfusion within the proced-
ures to allow cell attachment. Micro-imaging showed that 68% ±
8% (n = 5) of the portal vein and 78.3% ± 18% (n = 4) of the cen-
tral vein were repopulated as compared to data from control rat
livers (Figure 4B). Histologic analysis of individual vessels
showed microvascular endothelial cell coverage on the interior
of the portal vein at 86% ± 5% (n = 7) and of the central vein at
81% ± 9% (n = 7) as compared to data from control rat livers (Fig-
ure S5C). Next, using the best protocol consisting of seeding 40
million hiPSC-VECs or hNMVECs through both the vena cava
and then the portal vein of decellularized rat livers, we found
that vascular-endothelial-cell coverage was 75% ± 10% (n = 3)
using hiPSC-VECs and 85% ± 9% using control hNMVECs.
Two days after, assembled liver vasculature, populated with
either hiPSC-VECs or control hNMVECs, expressed CD31,
eNOS, and vWF (Figure 4C). In addition, two days after engraft-Figure 3. Generation and Characteristics of Cholangiocytes from Hum
(A) Schematic representation of the protocol generated to differentiate human iPS
fibroblast growth factor; RA, retinoic acid; DEX, dexamethasone; EGF, epiderma
like protein 1, Delta-1.
(B) Immunostaining analysis showing the proportion of CK7, CK19, SRY-BOX 9 (S
HFHs (gestational age; week 23) and human fetal liver tissue (gestational age: wee
cholangiocyte-specific genes, SOX9; HNF1b; cystic fibrosis transmembrane cond
and hepatocyte-specific genes HNF4a, LXR, and UGT1A1 in populations at diff
b-actin and presented as fold change relative to the expression in HFHs, which
tocytes; HNF, hepatocyte nuclear factor; CFTR, cystic fibrosis transmembrane
curonosyltransferase. ANOVA with Wilcoxon test compared between iPS-Chol a
represent mean ± SD of three independent experiments.
(C) Representative images demonstrating active export of the fluorescent bile ac
controls loaded with fluorescein isothiocyanate (FITC). Also shown is fluorescenc
normalized to background, **p = 0.0001 (two-tailed t test). Results are represent
(D) Assembly of whole organ bile duct in decellularized rat livers was achieved by
seeding protocols, a human cholangiocyte cell line (MMNK-1) was used and imag
3Dmicro-CT angiography of normal and decellularized liver bile duct is shown (n =
images of micron-sized iron oxide particle-labeled MMNK-1 seeded into the bile
bile duct repopulation is also shown compared to control paired micro-CT imag
(E) Hematoxylin and eosin staining and immunostaining of the recellularized liv
cellularized liver. Human fetal liver tissue (middle, gestational age; week 22) andment, expression of genes important in vascular biology was
increased when assembled in the liver vasculature, especially
when hiPSC-VECs were used (Figure 4D; Table S1). The gene
expression array analysis was confirmed by mRNA qPCR for
vascular endothelial growth factor (VEGF), vascular endothelial
growth factor receptor (VEGFR), hypoxia-inducible factor 1
alpha (HIF1a), and tissue-type plasminogen activator (PLAT),
where expression in assembled liver vasculature engrafted
with hiPSC-VECs was significantly higher when compared to
those measured in static culture controls (VEGF, p = 0.008, n =
3; VEGFR, p = 0.0005, n = 3; HIF1a, p = 0.002, n = 3; and
PLAT, p = 0.0004, n = 3; Figure 4E). The fibrinolytic function of
the engineered liver vasculature was further evaluated by as-
sessing the secretion of tissue plasminogen activator (tPA; Krui-
thof and Dunoyer-Geindre, 2014; Medh et al., 1992) in 2D fibro-
nectin static culture (Figure 4F) and we found that the highest
stimulation was achieved with PMA (phorbol 12-myristate 13-
acetate) in control hNMVECs. PMA-stimulated-tPA secretion
by hiPSC-VECs in assembled liver vasculature was significantly
superior to 2D fibronectin static culture (p = 0.002, n = 3). PMA-
stimulated-tPA secretion in control hNMVECs was not signifi-
cantly different. Next, we documented metabolic function of
the newly constructed liver vasculature composed of hiPSC-
VECs and hNMVECs by evaluating the uptake and metabolism
of a fluorescent acetylated low-density lipoprotein (Ac-LDL;
Voyta et al., 1984) using confocal microscopy (Figure 4F). This
analysis documented the three-dimensional structure of the por-
tal and central venous system (Figure 4F). Thus, hiPSC-VECs
were functional and reactive in the engineered liver (Figures 4E
and 4F) when compared to standard 2D static culture.
Assembly of Human iPSC-Derived Liver Grafts
After developing protocols for the differentiation and maturation
of human iPSCs into hepatocytes and cholangiocytes and
testing the capacity of hiPSC-VECs following recellularization
of decellularized livers, we repopulated all of the compartments
of liver grafts to study lineage interactions and function in a liveran-iPSCs
Cs into cholangiocytes (iPSC-Chol). BMP, bone morphogenetic protein; FGF,
l growth factor; IL, interleukin; TGF, transforming growth factor; sDLL-1, Delta-
OX9), and AFP in the differentiating population at day 13 and day 23 of culture.
k 22) were used as control. Also shown: qRT-PCR analyses of the expression of
uctance regulator (CTFR); inositol 1,4,5-trisphosphate receptor, type 3 (ITPR3);
erent stages generated from human iPSCs. Values are determined relative to
is set as 1. HEHBD, human extrahepatic bile duct; HAHs, human adult hepa-
conductance regulator; LXR, liver X receptor; UGT, uridine diphosphate glu-
t day 13 and day 23 for CFTR: *p < 0.05 and for ITPR3: **p < 0.001. Error bars
id CLF from the lumen of human iPSC-cholangiocyte organoids compared to
e intensity in the center of organoids. Mean intraluminal fluorescence intensity
ative of three independent differentiation experiments.
seeding cholangiocytes directly to the main bile duct. To optimize initially cell-
ing evaluations were performed and then iPSC-Chol were used for all studies.
5). Scale bars, (micro-CT) 1 cm, (micro-MRI) 4 mm. Representative micro-MRI
duct of decellularized livers at different depth levels. Quantification of the liver
e (n = 5).
er with iPSC-Chol, which were seeded through the biliary system of the de-
Human adult liver tissue were used as control.
Cell Reports 31, 107711, June 2, 2020 7
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OPEN ACCESSarchitecture. Using a specially designed perfusion and organ
culture chamber, the biliary system was repopulated first, fol-
lowed by repopulation of the parenchymal space, and then
vascular system (Figure 5A). Although, hepatocytes constitute
most of the parenchymal space, supportive non-parenchymal
cells (mesenchymal stromal cells, endothelial cells, and fibro-
blasts) enhance structural polarity and cellular stabilization (Bha-
tia et al., 2014; Cohen et al., 2015; M€usch, 2014; Takebe et al.,
2013). Based on the normal cellular content of the hepatic lobule
(Soto-Gutiérrez et al., 2011a), the parenchymal space was there-
fore seeded with iPSC-Heps (25 million cells representing 71%),
hiPSC-VECs (5 million cells representing 15%), human mesen-
chymal stromal cells (hMSCs, 2.5 million cells representing
7%), and human fibroblasts (2.5 million cells representing 7%;
Figure 5B; Figure S5E). Following repopulation of the compart-
ments (Figure 5B), we found that 28% ± 3% (n = 3) of the cells
were positive for the replication marker Ki67 and human albumin
(hALB), whereas 19% ± 2% (n = 3) of cells in human fetal livers
(16W [16 weeks]) and 2% ± 1% (n = 3) of cells in human adult
livers were positive for both Ki67/hALB (Figure 5C), indicating
constant regenerative capacity. Moreover, only about 1% (n =
3) cells were double positive for Ki67 and the endothelial marker
(CD31) across all groups. We also found that 2.2% ± 1% (n = 3)
were double positive for Ki67 and the cholangiocyte marker CK7
in bioengineered human iPSC-livers; and 1% ± 1% (n = 3) in fetal
liver and 4.4% ± 1% in human adult livers were Ki67/CK7 posi-
tive (Figure 5C). As tissue organization and cell polarization are
critical for function and regeneration (M€usch, 2014), we exam-
ined tight junctions and cell-cell adhesion in the repopulated
grafts. To compare the liver-tissue formation and function abili-
ties of assembled human iPSC-livers to primary cells, we used
control-assembled liver grafts that were bioengineered from pri-
mary rat liver cells and normal liver tissue. We showed, by immu-
nostaining, that cell-adhesion molecule integrin-beta-1 (ITGB1)
was present within two days in the assembled human iPSC-liverFigure 4. Characterization of Human iPSC-Derived Vascular Endotheli
(A) Characterization of human iPSC-VECs showing homogeneous expression o
neonatal microvascular endothelial cells (hNMVECs) were used as control.
(B) Endothelial-cell seeding experiments into decellularized rat livers were perform
interval. To optimize initially cell-seeding protocols, a human liver endothelial ce
human iPSC-VECs or hNMVECs were used for all studies. Shown is 3D micro-C
(portal and central veins; left). Next, representative micro-MRI images of iron ox
decellularized livers. Quantification of the liver vasculature repopulation is also sh
CT) 1 cm, (micro-MRI) 4 mm.
(C) Hematoxylin and eosin staining and immunostaining of the recellularized liver t
through vena cava and PV of the decellularized liver. Human adult liver tissue (rig
(D) Euclidean hierarchical clustering analysis focusing on the key genes related to
differentially expressed in 2D culture versus assembled liver vasculature after rec
to human adult liver tissue). Green dots represent the genes expressed in the asse
red dots represent genes expressed at a higher level in 2D culture format when
(E) qRT-PCR-based analyses of themRNA expression of VEGF, VEGFR, HIF1, and
after recellularization with human iPSC-VECs or hNMVECs. Values shown are rela
tissue (human liver), which is set as 1. ANOVA with Wilcoxon test compared bet
graphs represent the mean ± SD of three independent experiments.
(F) Left panel: Fold change of tissue plasminogen activator (tPA) secretion in 2D cu
Vit D, vitamin D; RA, retinoic acid; PMA, phorbol 12-myristate 13- acetate. Right p
with hNMVECs and iPSC-VECs pre- and post-stimulation with PMA 1 mM. AN
vasculature: *p < 0.05 (n = 3). Bars in all graphs represent the mean ± SD of three
tissue after recellularization with human iPSC-VECs and hNMVECs with LDL (lef(Figure 5D) at levels similar to those found in control-assembled
liver grafts bioengineered using rat primary liver cells, adult rat
liver, and human fetal and adult livers. ZO-1 proteins, a compo-
nent of tight junctions, were present in assembled human iPSC-
livers at levels similar to that in rat and human adult livers, at
higher levels than grafts bioengineered with rat primary livers
cells (Figure 5D), while they are not expressed in human fetal
livers (24W; n = 3). Finally, Conexin-32 (Cx32), a hepatic enriched
gap-junction protein that is expressed in rat and human adult
liver, was not expressed in assembled human iPSC-livers or hu-
man fetal livers (24W), although it was detected in assembled
grafts repopulated with primary rat cells (Figure 5D). These re-
sults indicate that key structural proteins important for cell-cell
and cell-ECM are present in bioengineered human iPSC-derived
liver tissue, although the hepatocyte-hepatocyte transmem-
brane communication protein Cx32 was not induced in these
studies.
There was no significant difference between assembled hu-
man iPSC-livers and assembled livers using rat primary liver
cells in their ability to secrete bile acids (Figure 5E). Urea pro-
duction in 3D static cultures was improved when iPSC-Heps
were mixed with human iPSC-VECs, human MSCs, and human
fibroblasts, compared to iPSC-Heps alone (p = 0.0006, n = 3),
and urea production in assembled human iPSC-liver was not
different from that observed in assembled primary rat cell liver
grafts, but was significantly higher than that in 3D static cul-
tures (p < 0.0001, n = 3; Figure 5E). Assembled human iPSC-
liver expressed human albumin and the mature isoform of the
hepatic transcription factor HNF4a at similar levels to those
seen in human adult livers (Figure 5F), and did not express
AFP. Expression of CD31 for endothelial cells and CK7 for
bile-duct epithelial cells were expressed in assembled human
iPSC-livers at levels similar to that seen in human fetal and
adult livers. Finally, A1AT production by assembled human
iPSC-livers during culture-perfusion was not statisticallyal Cells (iPSC-VECs)
f endothelial markers, CD31, eNOS, and von Willebrand factor (vWF). Human
ed through inferior vena cava (IVC) and portal vein (PV) with a 6-h static culture
ll line (TMNK-1) was used and imaging evaluations were performed and then
T angiography of normal and decellularized rat liver vascular compartments
ide microparticle–labeled TMNK-1 seeded into the portal and central vein of
own compared to control-paired micro-CT images (n = 5). Scale bars: (micro-
issue with human iPSC-VECs (left) and hNMVECs (middle), which were seeded
ht) was used as control.
angiogenesis and anticoagulation of human iPSC-VECs and hNMVECs (genes
ellularization with human iPSC-VECs or human neonatal MVEC, and compared
mbled liver vasculature at a higher level when compared to 2D culture, whereas
compared to assembled liver vasculature.
PLAT in cell populations cultured in 2D format and assembled liver vasculature
tive to b-actin and presented as fold change relative to expression in adult liver
ween 2D culture and assembled liver vasculature: *p < 0.05 (n = 3). Bars in all
lture between post- and prestimulation by indicated factors and concentration.
anel: fold change of tPA secretion in 2D culture and assembled liver vasculature
OVA with Wilcoxon test compared between 2D culture and assembled liver
independent experiments. Acetyl LDL Uptake assay at 24 h in assembled liver
t) and without LDL (right).
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ture (Figure 5G).
Auxiliary Transplantation of Human iPSC-Liver Grafts
To examine the engraftment and function of bioengineered hu-
man iPSC-liver grafts in vivo, we performed auxiliary liver trans-
plantation (Matsubara et al., 2015) into immunocompromised
(IL2rg/; Mashimo et al., 2010), retrorsine-hepatectomy-pre-
conditioned rats (Laconi et al., 1999; Matsubara et al., 2015).
To assemble and transplant human iPSC-liver grafts, human
iPSCs were differentiated into iPSC-Heps and iPSC-cholangio-
cytes coordinately. Then, human liver grafts were assembled
(bile duct, parenchyma, and vascular compartment) as
described above during a two-day period, then regenerated liver
grafts were cultured for two days more before transplantation
(Figure S5E). Decellularized liver grafts were regenerated by first
seeding human iPSC-derived cholangiocytes into the bile duct.
A mix of iPSC-Heps (71%), hiPSC-VECs (15%), hMSCs (7%),
and human fibroblast (7%) was then seeded into the paren-
chymal space, and hiPSC-VECs were used to regenerate the
liver-graft vascular system. Adequate perfused flow was corrob-
orated in thebioengineered human iPSC-liver grafts (Figure S6A).
In an effort to improve any thrombogenesis caused by platelet
adhesion to the liver matrix, 1–2 h before auxiliary liver transplan-
tation all bioengineered human iPSC-liver grafts were treated
with N-hydroxysuccinimide-polyethylene glycol (NHS-PEG; De-
glau et al., 2007), which has proved to block platelet deposition in
injured vascular surfaces (Deglau et al., 2007; Figures S6B and
S6C). We modified the decellularized liver ECM surface with N-
hydroxysuccinimide-polyethylene glycol (NHS-PEG) conjugated
to biotin for the purpose of detection, and found that about 46%
± 5.4%of the free space of a decellularized liver was coated (Fig-
ure S6B). Moreover, coated livers were perfused with blood
in vitro through the portal vein for 15 min. Thrombus formation
was notably reduced in coated-versus-uncoated decellularized
livers as indicated by the platelet marker CD41 (Figure S6C).
Moreover, heparin was added to the perfusion medium justFigure 5. Hepatic Function and Characterization of Engineered Human
(A) Photograph illustrating the organ perfusion and culture chamber used to rec
mesenchymal stem cells, and iPSC-Chol.
(B) Decellularized whole liver matrix (left) and liver after recellularization (right).
(C) Double-immunofluorescence staining for Ki67 and ALB, CD31, and cytokeratin
liver (gestational age; week 16) and adult liver tissues were used as the controls. B
for each cell type.
(D) Immunofluorescence staining for the key markers of cell adhesions and tigh
generated human liver grafts. Bioengineered livers with primary rat liver cells, hu
(E) Left: the comparison of bile-acid production between assembled liver grafts
iPSCs. Right: regenerated liver tissue assembled with human iPSC-human deriv
cultured alone in static sandwich (iPSC-Heps [3D]) and human iPSC-Heps culture
fibroblasts (iPSC-Heps mix [3D]). HFHs and HAHs cultured in static sandwich we
assembled liver, ANOVA with Wilcoxon test was used: *p < 0.05 (n = 3). Bars in all
represent mean ± SD of three experimental experiments.
(F) Characterization of human liver graft entirely regenerated from iPSC-derived
HNF4a and ALB, but no expression of AFP and ALB was detected. Also, double-
and eosin. Hoechst (blue stain) was used as counterstaining.
(G) A1AT production from regenerated liver tissue assembled with human iPSC-
iPSC-Heps cultured alone in static sandwich (iPSC-Heps [3D]) and human iPSC
stem cells, and fibroblasts (iPSC-Heps mix [3D]). HFHs and HAHs cultured in sta
mean ± SD of three experimental experiments.before the transplant procedure. A right nephrectomy was per-
formed to create space for the donor liver (Figures 6A and
6A1), and the portal vein and inferior vena cava (IVC) were
dissected (Figures 6A and 6A2). End-to-side anastomosis was
then performed between the donor and recipient IVC, and sub-
sequently between the donor and recipient portal vein (Figures
6A, 6A3, and 6A4). The donor-liver bile duct was stented and
inserted into the recipient duodenum. Homogeneous blood
perfusion throughout the regenerated grafts was observed
immediately after reperfusion (Figures 6A, 6A5, and 6A6). Finally,
in an effort to induce regeneration, the left lateral lobe of the
recipient rat was removed.
Transplanted animals (n = 5) were sacrificed at four days after
auxiliary liver transplantation. The causes of mortality observed
were ileus with poor blood flow into the graft (n = 2), portal vein
thrombosis (n = 1), and intestinal ischemia (n = 2). Harvested hu-
man iPSC-liver grafts measure 2.5–3 cm and showed liver-like
tissue texture (Figure 6B). Histological staining indicated that
the hepatocytes retained their morphology and their paren-
chymal positions (Figure 6C). Immunohistochemical staining
for human-specific albumin confirmed that hepatic function
was also retained in the transplanted grafts and was localized
in proximity to vessels as the human-specific CD31 staining indi-
cated endothelial cell function (Figure 6C). Grafts presented
scattered bile-duct-like structures that stained positive for
human-specific CK7 in proximity to human-specific albumin-
positive tissue. However, there was no anatomical evidence of
bile-duct-duodenal-functional reconnection. Human iPSC-liver
graft function was evaluated by detection of human serum
A1AT and albumin (Figure 6D). Human serum A1AT in trans-
planted rats was 7.7 ± 9.4 ng/mL and the levels of human serum
albumin were 5.6 ± 2.7 mg/mL at the endpoint of the study
(Figure 6D). In comparison, to investigate the efficiency of trans-
planting primary cell-bioengineered liver grafts in retrorsine-
conditioned and hepatectomized rats, engineered livers were
assembled using the same approach described above, but using
primary rat cells and an independent study was performed (n =iPSC-Derived Liver Graft
ellularized rat livers with human iPSC-Heps, iPSC-VECs, human fibroblasts,
7 (CK7) of regenerated liver grafts four days after recellularization. Human fetal
ar graphs showing the levels of Ki67 positive cell percentage are also indicated
t junctions, integrin beta-1 (ITGB1), ZO-1, and Conexin32 (CX32), of the re-
man fetal liver, human adult liver and rat adult liver were used as controls.
derived from rat hepatocytes and assembled liver grafts derived from human
ed cells (assembled human iPSC-liver) in comparison to that from iPSC-Heps
d with iPSC-VECs, iPS-derived cholangiocytes, mesenchymal stem cells, and
re used as the control in all experiments. To compare between 2D culture and
graphs represent the mean ± SD of three independent experiments. Error bars
cells four days after recellularization, showing homogeneous expression of
immunofluorescence staining for CD31 and CK7 are shown. H&E, hematoxylin
human derived cells (assembled human iPSC-liver) in comparison to that from
-Heps cultured with iPSC-VECs, iPSC-derived cholangiocytes, mesenchymal
tic sandwich were used as the control in all experiments. Error bars represent
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Figure 6. Auxiliary Liver Transplantation of the Engineered Human Liver Graft Derived from iPSCs
(A) Schematic representation of the auxiliary liver graft transplantation surgical technique for transplantation of human engineered liver grafts. Representative
images of graft transplantation: (1) after right nephrectomy, (2) PV) and IVC were exposed. (3) IVC anastomosis (end to side). (4) PV anastomosis (end to side). (5)
After reperfusion. (6) Before closing abdomen.
(B) Microscopic finding of the iPSC-liver graft three to four days after transplantation.
(C) Double-immunofluorescent staining of recellularized auxiliary graft after transplantation (left), compared to human adult liver tissue (middle), and rat recipient
liver (right). H&E, hematoxylin and eosin; h-ALB, human-specific albumin; h-CD31, human-specific CD31; h-CK7, human-specific cytokeratin 7. Sections were
counterstained with Hoechst (blue stain).
(D) The serum concentration of human specific A1AT and human-specific ALB was identified at four days after transplantation of assembled human iPSC-liver by
ELISA (n = 5). Bars represent the mean ± SD of five independent experiments.
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OPEN ACCESS8). The recipient survival rate over one week was 50% (n = 4) and
at twoweeks was 25% (n = 2). Early death-related complications
(<3 days) were due to portal vein thrombosis (n = 2) or technical
errors (n = 2), and the causes of death at one weekwere infection
and ileus with poor blood flow into the graft (Figure S6D).
DISCUSSION
Generating implantable bioengineered autologous liver grafts
using patient-derived cells would provide an alternative strategy
for the treatment of patients with terminal liver failure. In this
study, we show that an organ-like microenvironment can
improve the differentiation of specialized liver lineages in the12 Cell Reports 31, 107711, June 2, 2020parenchymal compartments (hepatocyte, cholangiocyte, and
vascular endothelial cells) and demonstrate that acellular liver
scaffolds repopulated with specialized cells derived from human
iPSCs produced human grafts that showed significant hepatic
function in vitro and in vivo after transplantation into immunode-
ficient rats as determined by human serum albumin, A1AT, and
postmortem histology.
The goal of decellularization is to remove cells while maintain-
ing the structural, mechanical, and biochemical properties of the
ECM scaffold. Numerous whole-organ decellularization proto-
cols have been reported, each with different effects on the
ECM (Soto-Gutiérrez et al., 2012). Before in vivo studies, it is diffi-
cult to determine which factors are important to success. Here
Article
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OPEN ACCESSwe incorporated DSC monitoring of ECM proteins to more care-
fully evaluate the micromechanical and biological properties of
the decellularized ECM. Liver decellularization required a con-
centration of Triton X-100 30 times lower than in our previous
protocol (Soto-Gutiérrez et al., 2011b) and generated a larger
collagen content and improved ECM protein structure and ther-
mal stability. DNA content, a commonly used marker of decellu-
larization, was 3–10 times higher than in previous studies
(Baptista et al., 2011; Soto-Gutiérrez et al., 2011b; Uygun
et al., 2010), which may lead to an adverse immune response if
animal-derived scaffolds are to be used in humans, however,
this remains to be tested.
In initial engineering studies, including our own, liver scaffolds
were seeded with primary animal or fetal cells (Baptista et al.,
2011; Kojima et al., 2018; Soto-Gutiérrez et al., 2011b; Uygun
et al., 2010; Yagi et al., 2013). Very recently, we have bio-
fabricated human fatty mini livers using genetically engineered
human iPSCs differentiated into hepatocyte-like cells and
grafted them, together with supporting cells, into an empty liver
scaffold tomimicmany aspects of human fatty liver disease (Col-
lin de l’Hortet et al., 2019). However, the entire liver vasculature
and the bile-duct system were not reconstituted. Here we devel-
oped a strategy for producing hepatocytes and cholangiocytes
from human iPSCs and demonstrate improvements in gene
expression and function when the human iPSC-derived endo-
thelial cells were seeded into a liver architecture where different
cell lineages were allowed to interact. We present techniques for
repopulation of the biliary, parenchymal, and vascular compart-
ments of a decellularized liver using five different cell types that
include human iPSC-derived hepatocytes, cholangiocytes, and
vascular endothelial cells, as well as mesenchymal stromal cells
and fibroblasts, to rebuild the liver microarchitecture. Finally, we
demonstrate the feasibility of transplanting these functional hu-
man bioengineered liver grafts.
Human iPSCs are generated by forced expression of specific
pluripotency transcription factors (Takahashi et al., 2007). Great
progress has been made investigating the hepatocyte differentia-
tion capacity of iPSCs. Although specific culture conditions can
vary, most protocols share a three-step strategy based on liver
ontology (Basma et al., 2009; Carpentier et al., 2014; Si-Tayeb
et al., 2010; Song et al., 2009; Soto-Gutiérrez et al., 2007a,
2007b) and follow the natural stages of liver development (Zaret
and Grompe, 2008). Despite progress in advancing the differenti-
ation of human stem cells into hepatocytes in vitro, cells that repli-
cate the ability of human primary adult hepatocytes to metabolize
drugs in vitro or can proliferate and replace livers for clinical appli-
cations has not been achieved. Most cells usually have a fetal
phenotype and immature function (Chen et al., 2018; Rezvani
et al., 2016). We have reported a guide to help standardize the
analysis of the maturation degree of hepatic-like cells across lab-
oratories by providing a dataset of the expression of 62 genes ex-
pressed in 17 fetal and 25 mature human livers (Zabulica et al.,
2019) and showed that the main similarities of human iPSC-
Heps and human fetal hepatocytes are related to the expression
and function of drug metabolism. Clinical application of bio-
engineered, autologous liver grafts will require the generation of
high numbers of iPSC-Heps with functionality equal to that of pri-
mary human hepatocytes. Building on our own previous work(Basma et al., 2009; Soto-Gutiérrez et al., 2006, 2007b), we devel-
oped a chemically defined system to generate functional hepato-
cytes with some characteristics of mature phenotype, especially
related to expression of clinically relevant liver-specific enzymes
(UGTA1 and FAH), mitochondria content, and secretion of liver-
specific proteins (A1AT and ALB; Basma et al., 2009; Carpentier
et al., 2014; Si-Tayeb et al., 2010; Song et al., 2009). Based on
nutritional components that promote hepatocyte maturation
occurring after birth (Chen et al., 2018), we added a maturation
stage that incorporates the low-glucose, cholesterol, and fatty
acids present in maternal milk (Ballard and Morrow, 2013), ste-
roids and bile acids (Chen et al., 2018) that stimulate nuclear re-
ceptors, and drugs and growth factors important for hepatocyte
function (Michalopoulos, 2007). Using this strategy, we were
able to extinguish AFP expression (a sign of hepatocyte matura-
tion), maintain expression of hepatocyte-enriched transcription
factors important for hepatocyte function, induce expression of
clinically relevant enzymes and hepatocyte-specific miRNAs,
and induce mitochondria levels equal to or higher than those
observed in freshly isolated primary human adult hepatocytes.
We also present a protocol for generation of cholangiocytes
from human iPSCs that allowed for early biliary specification,
as previously published (Sampaziotis et al., 2015), but also effec-
tively transformed human iPSC-derived hepatoblasts into chol-
angiocyte progenitors. To enhance natural bile duct maturation,
we added a differentiation stage based on the role of Notch and
TGFb signaling (Clotman et al., 2005; Flynn et al., 2004) as well as
signaling through IL6 and EGF. These factors induced expres-
sion of the mature cholangiocyte markers SOX9, CK19, and
CK7, and in most cells eliminated AFP expression. Importantly,
CFTR and ITPR3 membrane transporters known to be ex-
pressed on mature bile ducts were induced (Sampaziotis et al.,
2015; Turner et al., 2011).
Several protocols have been reported on the production of
functional vascular endothelial cells from human iPSCs (Olmer
et al., 2018; Prasain et al., 2014; Ren et al., 2015). We used
commercially available human iPS-VECs for our studies. They
functioned and expressed primary human neonatal vascular
endothelial cell markers (CD31, eNOS, and vWF) and had com-
parable ability to reconstitute vascular lumens of decellularized
livers, reaching nearly 75% of that found in the native liver.
Importantly, human iPS-VECs show expression of genes impor-
tant for angiogenesis and anticoagulation when assembled in the
vascular space.
Two-dimensional differentiation fails to recapitulate cell inter-
actions important for organogenesis and maturation. The
three-dimensional assembled liver grafts generated complex or-
gan-like tissues, and we found that assembled human iPSC-liver
and assembled rat livers were functionally comparable. Howev-
er, hepatocyte-specific CX32 was not induced in the assembled
human iPSC-livers, indicating that the bioengineered human
iPSC-derived liver tissue was still immature. Nevertheless,
some functions—namely urea production—were significantly
improved in the assembled human iPSC-liver, indicating that
the presence of non-parenchymal cells (human iPSC-VECs,
MSCs, and fibroblasts) could play a role in hepatocyte functions,
which is consistent with previous studies (Soto-Gutiérrez et al.,
2006; Takebe et al., 2013).Cell Reports 31, 107711, June 2, 2020 13
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and the parenchymal space, we seeded the bile duct directly in a
multistep fashion that led to coverage approaching 65% of that
found in the native liver. Whether these cells functionally inte-
grated into the graft is not known. Because hepatocytes are nor-
mally surrounded by ECM and many of their functions are regu-
lated by neighboring nonparenchymal cells (Chen et al., 2018;
Soto-Gutiérrez et al., 2006), we added human iPSC-VECs,
MSCs, and fibroblasts to iPSC-Heps to repopulate the lobular
space. Seeding into the parenchymal compartment is highly effi-
cient (Soto-Gutiérrez et al., 2011b; Uygun et al., 2010) because
of the lack of an endothelial barrier. Finally, we used a previously
reported technique that achieved high efficiency vascular
coverage of decellularized lungs (Ren et al., 2015) for our studies.
Our study provided the opportunity to examine the role of
nutritional and organ-structure-like microenvironment in each
human iPSC-derived hepatic cellular type (hepatocytes, cholan-
giocytes, and vascular endothelial cells). Recent reports high-
light the role of the multicellular components (Camp et al.,
2017) and nutritional changes (Avior et al., 2015; Schaub et al.,
2018), which impact liver differentiation and maturation. While
the auxiliary transplantation studies focus on the survival of the
human iPSC-derived mini livers, more work will be required to
test their efficacy to function and regenerate in animal models
of end-stage liver failure. This studywas limited by the small frac-
tion of liver-cell mass used and the vascular complications after
transplantation. Future studies should concentrate on proced-
ures to allow continued vascular development using, for
instance, nanoparticles and growth-factor-hydrogel modifica-
tion of acellular scaffolds that have proved to be a successful
approach to extend the life of bioengineered lungs after trans-
plantation (Nichols et al., 2018). Moreover, future studies should
investigate further maturation of the human iPSC-derived liver
grafts in vivo and establishment of bile canaliculus and hepatic
artery flow. The strategy shown here represents a significant
advance toward our understanding of the production of bio-
engineered autologous human-liver grafts for transplantation.STAR+METHODS
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Recombinant Human Epidermal Growth
Factor (rhEGF)
Lifeline Cell Technologies LS-1046
Recombinant human Insulin Growth Factor
1 (rhIGF-1)
Lifeline Cell Technologies LS-1014
Retinoic acid Sigma Aldrich R2625-50MG
Retrorsine Sigma Aldrich R0382
Rifampicin Sigma Aldrich R3501
RT2 SYBR Green ROX qPCR Mastermix QIAGEN 330500
sDLL-1 PeproTech 140-08
Sp-8-Br-cAMPs Life Science Institute B029
Strepto-avidin Phycoerythrin Thermo Fisher Scientific S866
TaqMan Fast Advanced Master Mix Thermo Fisher Scientific 4444557
1x TE buffer Thermo Fisher Scientific 12090015
Thiamine Sigma Aldrich T1270
Trace Element B Corning 25-022-Cl
Trace Element C Corning 25-023-Cl
Transforming Growth Factor-b1 Millipore GF111
Trypsin-EDTA (0.05%), phenol red Sigma Aldrich 25300054
Urso deoxycolic acid Sigma Aldrich U5127
Critical Commercial Assays
ABC Goat kit Vecastain Cat#PK-6105
ABC Mouse kit Vectastain Cat#PK-4000
ABC Rabbit kit Vectastain Cat#PK-6101
Bile acid assay kit Sigma Aldrich Cat#MAK309
3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide (MTT) assay
R&D Systems Cat#4890-025-K
Genomic DNA purification kit Promega Cat#A1120
RT2 Profiler PCR Array Human Endothelial
Cell Biology (PAHS-015Z)
QIAGEN Cat#330231
MEGAscript system Thermo Fisher Scientific Cat#AM1338
Human Alpha-1-Antitrypsin ELISA Kit Bethyl Cat#E88-122
Human NHDF Nucleofector kit Lonza Cat#VPD-1001
Human tissue plasminogen activator ELISA
Kit
Abcam Cat#ab108914
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Hydroxyproline Assay Kit Sigma Adrich Cat#MAK008
P450-GloTM CYP3A4 Assay (Luciferin-IPA) Promega Corporation Cat#V9001
RNeasy mini kit QIAGEN Cat#74104
SuperScript III First-Strand Synthesis
System
Thermo Fisher Scientific Cat#18080-051
Triglyceride Colorimetric Assay Cayman Chemical Company Cat#10010303
viPS lentiviral gene transfer kit Thermo Fisher Scientific https://www.thermofisher.com/
Experimental Models: Cell Lines
Adipose-Derived mesenchymal Stem Cells;
Normal, Human
American Type Culture Collection (ATCC) PCS-500-011
Human neonatal microvascular endothelial
cells
Lonza CC-2543
iCell Endothelial Cells, 11713 Cellular Dynamics, Fujifilm C1114
Rat microvascular endothelial cells VEC Technologies, Inc https://www.vectechnologies.com/
endothelial-cells/rat/
Cryopreserved rat dermal fibroblast Cell Applications, Inc R106-05a
Oligonucleotides
Alpha-1 antitrypsin Life Technologies Hs01097800_m1
ATP-binding cassette, sub-family A (ABC1),
member 1
Life Technologies Hs01059118_m1
Beta Actin Life Technologies Hs01060665_g1
CCAAT-enhancer binding protein alpha Life Technologies Hs00269972_s1




Cytochrome P4502C8 Life Technologies Hs02383390_s1
Epidermal growth factor receptor Life Technologies Hs01076078_m1
Factor five Life Technologies Hs00914120_m1
Other Oligonucleotides See Table S4 N/A
Recombinant DNA
pCXLE-EGFP Okita et al., 2011 Addgene, Cat#27082
pCXLE-hOCT3/4-shp53-F Okita et al., 2011 Addgene, Cat#27077
pCXLE-hSK Okita et al., 2011 Addgene, Cat#27078
pCXLE-hUL Okita et al., 2011 Addgene, Cat#27080
Software and Algorithms
Amaxa 4D-Nucleofector Lonza N/A
HP ChipScnner Affymetrix Inc https://www.affymetrix.com
ImageJ areas quantification and Gel
analysis tool
NIH https://imagej.nih.gov/ij/
Image Lab Bio-Rad https://iwww.bio-rad.com/
Inveon micro-CT system Siemens Medical Solutions https://www.siemens-healthineers.com











NanoDrop Thermo Scientific https://www.thermofisher.com/
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NIS-Elements AR Nikon https://www.nikoninstruments.com/
OsiriX NEWTON GRAPHICS https://www.newton-graphics.co.jp
Prism 7 GraphPad https://www.grapgrap.com/
StepOnePlus system Applied Biosystems https://www.thermofisher.com/
7 Tesla micro MRI system Bruker Biospin https://www.brunker.com
Tzero crucibles, loaded onto Q2000
differential scanning calorimeter
TA Instruments https://www.tainstruments.com/




mmu-miR-122-5p Life Technologies Cat#2245
mmu-miR-148a-3p Life Technologies Cat#470
mmu-miR-194-5p Life Technologies Cat#493





Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Alejandro
Soto-Gutierrez, MD, PhD (als208@pitt.edu).
Materials Availability
This study did not generate new unique reagents.
Data and Code Availability
Themicroarray data is available at theMendeley data repository, https://data.mendeley.com/datasets/ncxxgwdwty/1: Gene expres-
sion changes during human liver development: fetal toward adult. The microarray data can be accessed directly via its project DOI
(https://doi.org/10.17632/ncxxgwdwty.1) (Fraunhoffer and Soto-Gutiérrez, 2018).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
Sprague-Dawley male rats (200-250 g) (Charles River Laboratories, San Diego, CA) were used for liver harvest for whole-organ
decellularization, and auxiliary liver transplantation studies. Homozygous F344-Il2rgttm1Kyo rats were used as recipients and were es-
tablished by T.M. and obtained from the National Bio Resource Project for the Rat in Japan. The animals were cared for in accordance
with the guidelines set by the Committee on Laboratory Resources, National Institutes of Health, and Institutional Animal Care Com-
mittee of University of Pittsburgh.
Primary human fetal and adult hepatocytes
De-identified tissues were obtained fromMageeWomen’s Hospital (Pittsburgh, PA) and the University of Washington Department of
Pediatrics, Division of Genetic Medicine, Laboratory of Developmental Biology (Seattle, WA) after obtaining a written informed con-
sent by a protocol approved by the HumanResearch ReviewCommittee of theUniversity of Pittsburgh (Honest broker approval num-
ber HB015 and HB000836). Human fetal hepatocytes were isolated and culture from fetal livers as previously described (Tobita et al.,
2016). The de-identified normal human liver cells were obtained through the Liver Tissue Cell Distribution System (Pittsburgh, PA)
after obtaining a written informed consent by a protocol approved by the Human Research Review Committee of the University of
Pittsburgh, which was funded by NIH Contract # HSN276201200017C. Adult human hepatocytes were also obtained from Ira J
Fox Laboratory at Children’s Hospital of UPMC, after obtaining a written informed consent by a protocol approved by the Human
Research Review Committee and the Institutional Review Board (IRB#: PRO12090466) of the University of Pittsburgh. For human
fetal or adult liver tissue and hepatocytes used in this study both genders were used (XX and XY) and the ages for fetal livers ranged
from 16 to 24 weeks of gestational age and for adult livers ages ranged from 32yo to 52yo. Specific information on age, gender and
cell viability of human liver tissue and hepatocytes used in this study is described in Table S2.e5 Cell Reports 31, 107711, June 2, 2020
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The lines used here were generated from human amnion cells and human fetal fibroblast. Reprogramming was done using two
different techniques. Human amnion iPSCs were obtained from Stephen C. Strom laboratory. For both methods iPSCs colonies
were isolated around 20-25 days after induction based on morphology. Reprograming of amnion cells was initiated using the
viPS lentiviral gene transfer kit (Thermo Fisher Scientific, Waltham, MA), following the manufacturer’s instructions, to ectopically ex-
press octamer-binding transcription factor 3/4 (OCT3/4), NANOG, SRY (sex determining region Y)-box 2 (SOX2), LIN28, Kruppel-like
factor 4 (KLF4), and C-Myc. Reprograming of fetal fibroblasts was performed using episomal plasmids vectors adapted from a pre-
viously described protocol (Okita et al., 2011). Briefly, for each nucleofection, 1million cells were resuspended in 100 uL of the Amax-
aTMNHDFNucleofector kit (Lonza,Walkersville, MD), containing 3 ug of each of the four episomal plasmids vectors encodingOCT3/4
and p53 shRNA, SOX2 and KLF4, L-MYC and LIN28, and enhanced green fluorescent protein (eGFP) (Addgene, Boston, MA). Cells
were nucleofected using the Amaxa 4D-Nucleofector (Lonza, Walkersville, MD) and plated in mTeSR1TM on human embryonic stem
cell–qualifiedMatrigel (Corning, NewYork, NY)-coated plates. The lineswere karyotyped and pluripotency validated by expression of
NANOG, OCT4 and membrane markers SSEA and TRA160 at different passages and regularly tested negative for mycoplasma
contamination. Both genders (XX and XY) iPSC lines had equal ability to differentiate into liver cells (Figures S4A–S4C).
METHOD DETAILS
Liver procurement and decellularization
The abdominal cavity was opened with longitudinal incision. Left phrenic vein, right renal artery and vein, right adrenal vein, lumber
vein, portal-esophageal shunt and pyloric vein were ligated in that order. A cannula (BD, Franklin Lakes, NJ) was inserted into com-
mon bile duct. After heparinization (200 U), cold phosphate buffered saline (PBS) solution was infused from the aorta. After ligation of
splenic vein, left renal vein and supra hepatic vena cava, liver was taken out from the abdominal cavity. On the back table, cuffs were
put into the portal vein and infra-hepatic inferior vena. Then the liver was frozen at 80C completely immersed in saline solution.
Frozen livers were thawed at 4C overnight washed with PBS 1 h through perfusion via portal vein at 2 ml/min. Livers were perfused
with 0.02% trypsin/0.05%EGTA (Sigma-Aldrich, St Louis,MO) for 2 hours at 37C followed by 3%Triton X-100/0.05%EGTA or 0.1%
Triton X-100/0.05% EGTA (Sigma-Aldrich, St Louis, MO) for 24-36 h. Finally decellularized liver was sterilized with 0.1% paracetic
acid solution (Sigma-Aldrich, St Louis, MO) for 2 hours. Next, decellularized livers were washed with sterilized PBS solution with
100 U/ml penicillin and 100 mg/ml streptomycin (Invitrogen, Carlsbad, CA) and 100 mg/ml gentamicin (Thermo Fisher Scientific, Wal-
tham, MA) and preserved at 4C up to 7 days.
Optimization of whole-liver decellularization
To generate and optimize a natural liver scaffold to recreate the liver microenvironment for hepatic maturation and tissue assembly
using different cell lineages from human iPSCs, we implemented decellularized rat livers. First, we measured collagen content and
found that 0.02% trypsin and 0.1%Triton X-100 retained 94%of the fibrillar collagen of the native liver, compared with 53%using our
previously published protocol of 0.02% trypsin and 3%Triton X-100 (Soto-Gutiérrez et al., 2011b) (n = 4) (Figure S1A). The capacity of
the ECM to support cell ingrowth and tissue remodeling depends on its structural and chemical characteristics (Sun et al., 2013).
Differential scanning calorimetry (DSC) (Sun et al., 2013) to measure ECM structural protein stability after decellularization with
0.1% Triton X-100 solution showed at least four transitional events during calorimetric scans between 2C and 125C, with onset
of denaturation occurring at 40C, 58C, 70C and 80C (Figure S1B). With the 3% Triton X-100 solution, the transitional events
at 70C and 80C were absent and the thermogram shifted to a lower temperature, indicating less protein stability (57.5 ± 0.3C
versus 54.9 ± 0.9C, 0.1% versus 3%, p value = 0.002 by Student’s t test, n = 4). As expected, fresh liver showed very small thermal
transitions due to the high cellular content. Residual DNA content after either decellularization protocols was < 10% that of native liver
but 3-10-fold higher compared with some previous protocols (Baptista et al., 2011; Soto-Gutiérrez et al., 2011b; Uygun et al., 2010)
(Figure S1C) (0.1% versus 3%, p = 0.999 by one-way ANOVA, Tukey-Kramer, n = 3). Both decellularization protocols demonstrated
complete cellular removal as evidenced by the DNA-binding stain Hoechst (Figure S1C). Scanning electron microscopy (SEM)
confirmed that collagen density was better preserved with the 0.1% Triton X-100 solution (Figures S1D and S1E). As the collagen
content, DSC data and imaging analysis suggested that the 0.1% Triton X-100 solution better preserves collagens and other
ECM elements, this protocol was selected for further study. Fibronectin and laminin components of the basement membrane
were preserved (Figure S1F). Furthermore, a qualitative proteomics analysis detected protein in the decellularized liver correspond-
ing to 15% that in the native liver. Gene Ontology analysis indicated the presence of important proteins involved in structural, mo-
lecular and biological functions in the decellularized liver (Figure S2; Table S3). However, some of the ECM proteins present might
have been missed in the proteomics analysis because they were not dissolved and trypsin digested.
DNA quantification
DNA content was measured using methods described previously (Gilbert et al., 2009; Soto-Gutiérrez et al., 2011b). In brief, the de-
cellularized liver was cut into small strips, weighted and digested using Proteinase K (Invitrogen) for 24–48 h at 50C until no visible
material remained. Phenol-chloroform-isoamyl alcohol (25:24:1; Acros) was then added in equal amounts to the decellularized liver
digest and centrifuged for 10 min at 10,000 g. The aqueous top layer containing the DNA was then removed and added to 200 mL of
3M sodium acetate solution to reduce RNA content. Ethanol was then added and the solution frozen at 80C for at least 12 h.Cell Reports 31, 107711, June 2, 2020 e6
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amount of DNA was quantified using the NanoDrop (Thermo) using the manufacturer’s instructions. The results were normalized
to the weight of liver tissue.
Collagen content
10mg of normal and decellularized 3% Triton and 0.1% Triton liver samples were hydrolyzed with 6N HCL at 120C for 3h. Hydroxy-
proline content was thenmeasured using a hydroxyproline assay (Sigma, St-Louis,MO) according to themanufacturer’s instructions.
The collagen content was calculated indirectly throughmeasurement of Hydroxyproline content according to Jamall et al. (1981). The
results were normalized to the wet weight of normal liver.
Differential scanning calorimetry (DSC)
Fresh liver tissue and decellularized extracellular matrices in PBS solution were blot-dried with Kimwipe paper to remove excessive
surface water. Samples were hermetically sealed in Tzero crucibles, loaded onto Q2000 differential scanning calorimeter (DSC) (TA
Instruments, New Castle, DE) between 20C and 30C, and pre-cooled at 3C/min to 2C before samples were scanned at 3C/min
up to 125C for thermo-physical analysis under a pure nitrogen purge flow rate of 50 mL per min. After DSC scan, small holes were
punched on the lids of crucibles, and samples were dried in a vacuum oven at 105C for at least 4 h to determine drymass. Data were
analyzed with the Universal Analysis software (Version 4.5A).
Proteomics assay
Fresh rat liver (n = 1) and decellularized rat liver (n = 1) samples were reduced, alkylated and trypsin digested according to the iTRAQ
protocol (Applied Biosystems). Peptides were analyzed by liquid chromatography-matrix assisted laser desorption ionization (LC-
MALDI) analysis using the Ultimate 3000 nano high pressure liquid chromatography (HPLC) system (Dionex) equipped with a Probot
(LC Packings) coupled to a 5800 MALDI time-of-flight/time-of-flight (TOF/TOF) Analyzer. Peptides were loaded onto a C18 Pep-
Map100, 3mm column (LC-Packings) and separated with a gradient of 10%–45% acetonitrile (0.1% trifluoroacetic acid) over 165mi-
nutes. Spectral data were analyzed using Mascot sequence matching software (Matrix Science) against the Ludwig NR database
with taxonomy set to Rattus norvegicus. The database contained 51,167 sequences. A list of the proteins analyzed can be found
in Table S3. Protein classification and categorization of biological process, cellular component and molecular function of the iden-
tified proteins according to Gene Ontology (GO) information obtained from European Bioinformatics Institute (EBI) at http://www.ebi.
ac.uk/GOA and http://ftp://ftp.ebi.ac.uk/pub/databases/GO/goa/UNIPROT/gene_%20association.goa_uniprot.gz.
Biological process, cellular component and molecular function categorization of the detected proteins were based upon GO iden-
tification numbers (ID #s) with relatively broad categories to better represent the data. Cellular component refers to the place in the
cell where a gene product is active. The molecular function is the elemental activities of a protein product at the molecular level. Bio-
logical process is defined as a biological objective to which the protein or protein product contributes (Ashburner et al., 2000). After
assigning GO ID#s, every GO termwas categorized as lower or upper categories andwere assigned in three different levels. The third
level categories with more than three or four GO proteins were represented in the bar graph for each of the three large categories
(Table S3).
Microarray analysis
Liver tissue from fetal and adult human samples was pooled for RNA isolation. Total RNA extraction and purification was performed
using QIAGEN RNeasy kit (QIAGEN, San Diego, CA). The first strand of cDNA was synthesized using the primer, while the second
strand was made at 16C by adding E. coli DNA ligase, E. coli DNA polymerase I and RnaseH to the reaction. To blunt the ends
of the cDNA synthesized, T4 DNA polymerase was added. cDNA was then purified by phenol/chloroform and ethanol precipitation.
Incubation of purified cDNA at 37C for 4 hours in an in vitro transcription reaction resulted in cRNA (labeled with biotin using MEGA-
script system). Then, for Chip hybridization; about 20 mg of cRNA were incubated in a buffer containing 200mM Tris-acetate (pH 8.1),
500mM KOAc and 150mM MgOAc at 95C for 35 minutes to fragment it. A pre-equilibrated Affymetrix chip was hybridized with the
fragmented cRNA at 45C for 14-16 hours before washing with a low stringency buffer (6X SSPE, 0.1% Tween 20, 0.005% antifoam)
for 10 cycles and a stringent buffer (100mMMES, 0.1 M NaCl, 0.1% Tween 20) for 4 cycles. This was followed by staining with SAPE
(Strepto-avidin Phycoerythrin) and incubation with biotinylated mouse anti-avidin antibody and restained with SAPE. An HP ChipS-
canner (Affymetrix Inc, Santa Clara, CA) was used to scan the chip to detect hybridization signals. To perform themicroarray analysis;
the processed intensity values (from SAM) were imported into R, and the oligo package was used to perform RMA (Robust Multi-
Array Analysis) normalization, which applies a background correction and log transformation to the data as well. Next, low expressed
genes were filtered out using genefilter. This workflow produced a processed ExpressionSet object with expression values for Affy-
metrix probe sets, to which gene annotation information was added using the annotate and hgu133a.db packages. Principle compo-
nent analysis (PCA) was performed on the samples. Finally, the limma package was used to apply an empirical Bayes statistical
model to calculate a moderated t-statistic and p value for each gene comparing its log-fold expression in adult samples relative
to all the fetal samples. 1204 differential expressed genes were identified, using an FDR of 0.05 to improve the stringency of further
analysis. Next, we performed GO term enrichment analysis using the topGO package in R to select ‘‘Molecular Function’’ GO terms
that were statistically enriched (based on a hypergeometric p value calculation with an FDR cutoff of 0.05) in the pool of differentiallye7 Cell Reports 31, 107711, June 2, 2020
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nonical pathways differentially expressed in fetal and adults, with the overlapping pathways being identified aswell. Network analysis
and Upstream regulator analysis was done using IPA as well. The microarray data is available at (https://doi.org/10.17632/
ncxxgwdwty.1) (Fraunhoffer and Soto-Gutiérrez, 2018).
Differentiation of human iPSCs into hepatocytes (iPS-Heps)
Our hepatocyte differentiation protocol is summarized in Figure 1A. Human iPSCs were passaged with Accutase (StemCell Technol-
ogies, Vancouver, Canada) and re-plated at a density of 1 to 2x105/cm2 growth factor reducedMatrigel (Corning Incorporated, Corn-
ing, NY) coated plates in mTeSR. The day after, cells were exposed to a defined differentiation medium containing RPMI (Invitrogen,
Carlsbad, CA), 1X B-27 w/o insulin supplement (Invitrogen, Carlsbad, CA), 0.5% Penicillin/Streptomycin (Millipore, Billerica, MA),
0.5% of Non-Essential Amino Acids (Millipore, Billerica, MA), 100 ng/ml Activin A (R&D Systems, Minneapolis, MN), 10 ng/ml
BMP4 (R&DSystems,Minneapolis, MN) and 20 ng/ml FGF2 (BD, Franklin Lakes, NJ) for two days and placed in a normal O2 incubator
(Stage 1, endoderm induction). Cells were subsequently maintained in a similar medium without FGF2 and BMP4 for two days in
ambient O2/5% CO2 incubator (Stage 2, definitive endoderm). Cells were then grown for 10 days in a defined medium containing
45% DMEM low glucose 1g/l (ThermoFisher Scientific, Waltham, MA), 45% F-12 (ThermoFisher Scientific, Waltham, MA), 10%
CTS KnockOut SR XenoFree Medium (ThermoFisher Scientific, Waltham, MA), 0.5%Non-Essential Amino Acids (ThermoFisher Sci-
entific, Waltham, MA), 0.5% L-glutamine (ThermoFisher Scientific, Waltham, MA), 50 ng/ml HGF (Kindly provided by George Micha-
lopoulos) and 1%DMSO (Sigma-Aldrich, Saint Louis, MO), mediumwas changed every other day (Stage 3, hepatic specification). At
the end of Stage 3, cells were detached and either re-plated at a 30%–40% confluence in 3D sandwich culture or seeded into de-
cellularized liver matrix for further maturation. Cells were grown for 4 days in a defined medium containing 45% DMEM low glucose
1g/l (ThermoFisher Scientific, Waltham, MA), 45% F-12 (ThermoFisher Scientific, Waltham, MA), 10% CTS KnockOut SR XenoFree
Medium, 0.5%Non-Essential Amino Acids (ThermoFisher Scientific,Waltham,MA), 0.5%L-glutamine (ThermoFisher Scientific,Wal-
tham, MA), 0.1% of Gentamicin/Amphotericin-B (ThermoFisher Scientific, Waltham, MA), 1% of Pennicillin/Streptomycin (Thermo-
Fisher Scientific, Waltham, MA), 50 ng/ml HGF (Kindly provided by George Michalopoulos), 1% DMSO, 0.5uM Dexamethasone
(Sigma-Aldrich, Saint Louis, MO), 0.1% of Ascorbic Acid (Sigma-Aldrich, Saint Louis, MO), 0.1% of Bovine Serum Albumin Free
of Fatty Acids, 0.1% of Hydrocortisone, 0.1% of Transferrin, 0.1% of Insulin (HCM Bullet Kit, ThermoFisher Scientific, Waltham,
MA), 100uM of Urso deoxycolic acid (Sigma-Aldrich, Saint Louis, MO), 20uM of Palmitic Acid (Sigma-Aldrich, Saint Louis, MO),
30 uM of Oleic Acid (Sigma-Aldrich, Saint Louis, MO), 20 uM of Rifampicin (Sigma-Aldrich, Saint Louis, Missouri) and 1x of Choles-
terol (ThermoFisher Scientific, Waltham, MA) (Stage 4, hepatic maturation).
Differentiation of human iPSCs into cholangiocytes
Our cholangiocyte differentiation protocol is summarized in Figure 3A. Human iPSCs were passaged with Accutase (StemCell Tech-
nologies, Vancouver, Canada) and re-plated at a density of 1 to 2x105/cm2 growth factor reduced Matrigel (Corning Incorporated,
Corning, NY) coated plates in mTeSR. The day after, cells were exposed to a defined differentiation medium containing RPMI (Invi-
trogen, Carlsbad, CA), 1X B-27 w/o insulin supplement (Invitrogen, Carlsbad, CA), 0.5% Penicillin/Streptomycin (Millipore, Billerica,
MA), 0.5% of Non-Essential Amino Acids (Millipore, Billerica, MA), 100 ng/ml Activin A (R&D Systems, Minneapolis, MN), 20 ng/ml
BMP4 (R&D Systems, Minneapolis, MN) and 10 ng/ml FGF2 (BD, Franklin Lakes, NJ) for two days and placed in ambient O2/5%
CO2 incubator (Stage 1, endoderm induction). Cells were subsequently maintained in a similar medium without FGF2 and BMP4
for two days in ambient O2/5% CO2 incubator (Stage 2, definitive endoderm). Cells were then grown for 5 days in a defined medium
containing RPMI (Invitrogen, Carlsbad, CA), 1X B-27 with insulin supplement (Invitrogen, Carlsbad, CA), 0.5% Penicillin/Strepto-
mycin (Millipore, Billerica, MA), 0.5% of Non-Essential Amino Acids (Millipore, Billerica, MA), 20 ng/ml BMP4 (R&D Systems, Minne-
apolis, MN) and 10 ng/ml FGF2 (BD, Franklin Lakes, NJ) at 4%O2/5%CO2 incubator (Stage 3, hepatic specification). To induce biliary
specification, cells were culture for another 4d in the presence of RPMI (Invitrogen, Carlsbad, CA), 1X B-27 w/o vitamin A (Invitrogen,
Carlsbad, CA), 0.5% Penicillin/Streptomycin (Millipore, Billerica, MA), 0.5% of Non-Essential Amino Acids (Millipore, Billerica, MA),
50 ng/ml FGF10 (R&D Systems, Minneapolis, MN), 50 ng/ml Activin A (R&D Systems, Minneapolis, MN) and 3 mM retinoic acid
(Sigma-Aldrich, Saint Louis, MO), medium was changed everyday (Stage 4, cholangiocyte induction). Finally, to induce cholangio-
cyte maturation, cells were culture in the presence of William’s E Medium (Invitrogen, Carlsbad, CA), 10mM Nicotinamide (Sigma-
Aldrich, Saint-Louis, MO), 17mM Sodium bicarbonate (Sigma-Aldrich, Saint-Louis, MO), 0.2mM 2-phospho-L-ascorbic acid
trisodium salt (Sigma-Aldrich, Saint-Louis, MO), 14mM Glucose (Sigma-Aldrich, Saint-Louis, MO), 20mM HEPES (Sigma-Aldrich,
Saint-Louis, MO), 1X ITS Supplement (BD Biosciences), 6.3mM Sodium pyruvate (Invitrogen), 0.1 mM Dexamethasone (Sigma-Al-
drich, Saint Louis, MO), 2mM Glutamax (ThermoFisher Scientific, Waltham, MA), 0.5% of Pennicillin/Streptomycin (ThermoFisher
Scientific, Waltham, MA), 20 ng/ml EGF (R&D Systems, Minneapolis, MN), 10 ng/ml human sDLL-1 (PeproTech, Rocky Hill, NJ),
5ng/ml TGFb1 (Millipore, Billerica, MA), 10ng/ml IL-6 (Miltenyi Biotec, San Diego, CA). The medium was changed every other day
and the cells were cultured for a total of 10 d (Stage 5, Cholangiocyte maturation). At the end of the differentiation protocol cells
were detached with and used for experiments.Cell Reports 31, 107711, June 2, 2020 e8
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Total RNA was isolated from human cells using RNeasy Mini kits (QIAGEN, Hilden, Germany) and reverse transcribed using Super-
Script III (Invitrogen, Carlsbad, CA) following the manufacturers’ instructions. We performed qPCR with a StepOnePlus system
(Applied Biosystems, Foster City, CA) using TaqMan Fast Advanced Master Mix (Life Technologies, Waltham, MA). The probes
used are listed in Key Resources Table. Relative gene expression was normalized to b-actin (ACTB) mRNA. Relative expression
was calculated usingDDCTmethod. MaturemiRNAs were amplified and quantified using TaqmanmiRNA probes (Life Technologies)
(Key Resources Table) and Taqman Universal Master Mix II (Life Technologies). Quantitative PCR reactions were performed using a
StepOnePlus System (Life Technologies). Expression values were normalized with Rnu6b, which is standard for miRNA profiling.
Relative expression was calculated using DDCT method. Quantitative real time PCR was performed also using Human Endothelial
Cell Biology PCR array (See Key Resources Table) following manufacturer’s recommendations. A list of the genes analyzed can be
found in Table S1. Genomic DNAwas prepared by using a genomic DNA purification kit (Promega,Madison,WI). mtDNA content was
analyzed by Sybr green quantitative PCR using primers amplifying NADH-ubiquinone oxidoreductase chain 1 (ND1)(Forward, 50-
cacccaagaacagggtttgt-30, Reverse, 50-tggccatgggatagttgttaa-30) normalized to ACTB (forward, 50-ggcatcctcaccctgaagta-30,
reverse, 50-gaaggtgtggtgccagattt-30).
Transmission electron microscopy
For human fetal and adult hepatocytes and iPS-Heps, cell monolayers were briefly washed with PBS solution. Samples were then
fixed with 2.5% glutaraldehyde for 1 hour at room temperature and washed with PBS. Samples were submitted to the University
of Pittsburgh Center for Biologic Imaging for post-fixation with 1% osmium tetroxide and 1% potassium ferricyanide for 1 hour at
room temperature. Samples were washed with PBS and dehydrated in a graded series of ethanol solution (30%, 50%, 70%, and
90% - 10 minutes each) and three 15-minute changes in fresh 100% ethanol. Infiltration was done with three 1-hour changes of
epon. The last change of epon was removed and beam capsules filled with resin were inverted over relevant areas of themonolayers.
The resin was allowed to polymerize overnight at 37C and then for 48 hours at 60C. Beam capsules and underlying cells were de-
tached from the bottom of the 6-well plate and sectioned. Image acquisition was done using either the JEM-1011 or the JEM-
1400Plus transmission electron microscopes (Jeol, Peabody, MA) at 80kV fitted with a side mount AMT 2k digital camera (Advanced
Microscopy Techniques, Danvers, MA).
Scanning electron microscopy
Normal fresh liver, decellularized 3% Triton and 0.1% Triton and recellularized (assembled vasculature) liver samples were fixed with
glutaraldehyde in preparation for scanning electron microscopy studies. Tissues for immunolabeling and SEM were prepared and
imaged as previously described (Soto-Gutiérrez et al., 2006, 2011b). Tissue samples were sectioned into small blocks (8mm3),
and were then fixed in 1%Osmium tetroxide for 60 minutes. Samples were dehydrated using graded series of alcohol for 15 minutes
each (30% ethanol, 50% ethanol, 70% ethanol, 90% ethanol, 100% ethanol). The samples were then dried at critical point for two
hours in absolute alcohol and mounted on an aluminum stub and sputter-coated with gold. Samples were imaged using JEOL 9335
Field Emission Gun.
Organ and cellular imaging
To compare the central and portal vasculature and bile duct between intact and decellularized rat liver, ex vivo liver micro-computed
tomography (-CT) was performed. Liver casting was performed with 10 mL 20% Bismuth chloride (MP biomedicals, Solon, OH) with
5% gelatin in PBS. 4% paraformaldehyde fixed (control) or decellularized liver was prepared as described above. The casting solu-
tion was injected through the portal vein, inferior vena cava and bile duct and the perfusion was stoppedwhen back pressure was felt.
The portal vein and inferior vena cava were ligated above and below the liver and the liver was incubated overnight at room temper-
ature to allow the bismuth-containing gelatin to solidify. Liver vasculature was quantified using a micro-CT system (Inveon micro-CT
system, Siemens Medical Solutions, Knoxville, TN). The image resolution and the field of view were set as 30 mm/voxel and 50mm x
50mm x 50mm, respectively with X-ray beam setting at 80kVe and 100mA with a 1000msec exposure time. Acquired pictures were
reconstructed and analyzed using OsiriX image processing software program.
To measure and optimize cell seeding within decellularized liver scaffold using micro- magnetic resonance imaging (-MRI), we
labeled human liver endothelial cells (TMNK-1) (Matsumura et al., 2004; Soto-Gutiérrez et al., 2006) or human cholangyocites
(MMNK-1) (Maruyama et al., 2004) with micron-sized iron oxide particles (Bangs Laboratories, Inc.). Iron oxide micro-particles
(1.63 mm) are magnetite cores encapsulated with styrene/divinyl benzene with dragon green fluorescent dye (480-nm excitation,
520-nm emission) soaked in (Kindly provided by Dr. Erik M. Shapiro; Shapiro et al., 2004). For labeling, cells were plated at a density
of 1 million cells/cm2 on plastic culture flasks and allowed to attach. Shortly after, 30 iron oxide microspheres/cell were added to the
growth medium, and incubated with the cells over night. To remove free particles after labeling, the cells were washed extensively to
remove loosely bound free particles. Normally, about 70% of the cells will contain 4-5 iron oxide microspheres (Figure S8A). The cells
were then released from the dish by incubation with trypsin and used for cell seeding and imaging studies. The cell assembled liver
scaffold was then fixed with 4% paraformaldehyde for 24 hours and then rinsed with neutral PBS twice, and the scaffold was placed
in a 60mm Petri dish (IWR) wrapped with polyvinylchloride (Saran Wrap, Dow Chemicals) film to prevent sample drying. The sample
was placed in a 72mm-internal diameter volume radiofrequency coil (Bruker Biospin Corporation, Billerica, MA) and the sample wase9 Cell Reports 31, 107711, June 2, 2020
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79 mm/voxel and 512x512X256 image size using a 7 Tesla micro MRI system (Bruker BioSpec 70/30 USR, Bruker BioSpin) with Para-
Vision Acquisition 5.0 software (Bruker, Biospin). For the analysis of cell distribution, different liver lobes were isolated and used for
micro MRI. Liver lobes were reconstructed with planar images. As a control of distribution analysis, images of native liver acquired by
micro CT were reconstructed to planar slices and compared. For pairing images, planar (2D) images (approximate slice thickness
1 mm) were obtained for each liver lobe. To allow accurate definition in image pairing the major branch of the portal vein, central
vein or bile duct was selected for each lobe andmanually traced and divided into interbranch segments for anatomical image pairing.
Segments were traced beginning at the largest portal vein, central vein or bile duct and moving along the major branch to the small-
est. The quantitative analysis of the obtained images of the structures of the liver lobes was performed using the OsiriX image pro-
cessing software program.
Liver assembly and organ culture
The liver assembly system consisted of a peristaltic pump, bubble trap and syringe infusion pump (Figure 5A). Freshly decellularized
rat liver graft (median, superior and inferior right lobes) was connected to the liver assembly system through a portal vein cannula. The
inferior vena cava was left open for outlet and the supra hepatic vena cava was ligated. Freshly decellularized rat liver was kept in
continuous perfusion through the portal vein. 30-50 mL of culture medium was used in the liver assembly system. Cuffs located
in the portal vein and infra-hepatic inferior vena cava allowed easy manipulation of the decellularized rat liver. The main bile duct
was also cannulated using a tubing adaptor (BD, Franklin Lakes, NJ). Cell delivery was achieved using a controlled syringe infusion
pump (Figure 5A) connected directly to themain bile duct or the perfusion tubing. After a 30-60min perfusion withmedium, first a total
of 6 million human iPSC-derived cholangiocytes were infused into the bile duct in four steps at 15-min intervals, each step 1.5 million
cells suspended in 0.5mL of medium were perfused over 5 min. Then, approximately 2 h later a mix of iPS-Heps (25 million cells rep-
resenting 71%), hiPS-VECs (5 million cells representing 15%), human mesenchymal stromal cells (hMSCs) (ATCC, Manassas, VA)
(2.5 million cells representing 7%) and human fibroblast (2.5 million cells representing 7%) were infused into the circuit in seven steps
at 10-min intervals and were recirculated in the system at room temperature. For the assembly of livers using rat primary cells; we
isolated rat hepatocytes using the two-step perfusion protocol as described by Dunn et al., (1991). Viability was assessed by trypan
blue exclusion test and was routinely > 90%. Primary rat microvascular endothelial cells (P4-P7) (VEC Technologies, Inc. Rensselaer,
NY) and primary rat fibroblasts (Cell Applications, Inc. San Diego, CA) were used aswell for histological, bile acid and urea production
studies. The engineered liver grafts were transferred to the liver culture system for 24 h with continuous flow at a rate of 15 ml/min for
3h, at 10 ml/min for the next 3h and finally at a rate of 2 ml/min for the remaining 18h.
Next, to assemble the liver vasculature, a total of 40million human iPS-VECs or human NMVECswere infused into the circuit in two
steps at 6 h intervals of no flow (to allow cell attachment) via the inferior vena cava (20million cells diluted in 10mL of medium) and the
portal vein (20 million cells diluted in 10mL of medium) each step was perfused over 5 min at a flow rate of 2 ml/min. The completely
engineered human liver graft was cultured for 36 h before functional or transplantation studies at a flow rate of 2 ml/min. The liver
culture system consisted of a peristaltic pump, bubble trap and oxygenator. The system was placed in an incubator for temperature
control, and the oxygenator was connected to atmospheric gas mixture. The graft was continuously perfused through the portal vein
at 2 ml/min with continuous oxygenation that delivered an inflow partial oxygen tension of 300 mm Hg. Liver assembly was per-
formed using 37% DMEM low glucose 1g/l (ThermoFisher Scientific, Waltham, MA), 37% F-12 (ThermoFisher Scientific, Waltham,
MA), 10%CTSKnockOut SRXenoFreeMedium (Thermo Fisher Scientific,Waltham,MA), 0.5%Non-Essential Amino Acids (Thermo-
Fisher Scientific, Waltham, MA), 1mM L-glutamine (ThermoFisher Scientific, Waltham, MA), 1% of Penicillin/Streptomycin (Thermo-
Fisher Scientific, Waltham, MA), 50 ng/ml HGF (Kindly provided by George Michalopoulos), 1% DMSO (Sigma-Aldrich, Saint Louis,
MO), 0.5 mM Dexamethasone (Sigma-Aldrich, Saint Louis, MO), 0.1% of Ascorbic Acid (Sigma-Aldrich, Saint Louis, MO), 1% of
Bovine Serum Albumin Free of Fatty Acids, 0.1% of Hydrocortisone, 0.1% of Transferrin, 0.1% of Insulin, 0.1% Gentamicin (GA-
1000) (HCM Bullet Kit, ThermoFisher Scientific, Waltham, MA), 100uM of Urso deoxycolic acid (Sigma-Aldrich, Saint Louis, MO),
1x of Cholesterol (ThermoFisher Scientific, Waltham, MA), 20uM of Palmitic Acid (Sigma-Aldrich, Saint Louis, MO), 30 uM of Oleic
Acid (Sigma-Aldrich, Saint Louis, MO), 20 uM of Rifampicin (Sigma-Aldrich, Saint Louis, Missouri), 5ng/ml recombinant human
Vascular Endothelial Growth Factor (rhVEGF) (Lifeline Cell Technologies, Frederick, MD), 5ng/ml recombinant human Endothelial
Growth Factor (rhEGF) (Lifeline Cell Technologies, Frederick, MD), 5ng/ml recombinant human basic Fibroblast Growth Factor
(rhbFGF) (Lifeline Cell Technologies, Frederick, MD), 15ng/ml recombinant human Insulin Growth Factor 1 (rhIGF-1) (Lifeline Cell
Technologies, Frederick, MD), 0.75 U/ml Heparin (Lifeline Cell Technologies, Frederick, MD), 10% iCell Endothelial Cells Medium
Supplement (Cellular Dynamics, Fujifilm, Madison, WI). Additionally, to prevent platelet activation in transplanted human liver grafts;
poly-ethylene glycol-carboxymethyl succinimidyl ester (NHS-PEG,MW5000) (NANOCS) was diluted in above describedmedium at a
concentration of 50mg/ml and the graft was perfused through the portal vein until the engineered liver was filled and soaked (approx-
imately 30ml). The engineered livers were incubated at 37C for 1 h before auxiliary liver graft transplantation was performed.
Functional analysis
For analysis of hepatocyte function in iPS-Heps and assembled liver grafts, culture media samples or blood serum were collected
and analyzed for human alpha-1-antitrypsin (A1AT) content using enzyme linked immunosorbent assay (ELISA) as described by
the manufacturer (Bethyl laboratories Inc, Montgomery, TX). Human serum albumin was analyzed by ELISA according to theCell Reports 31, 107711, June 2, 2020 e10
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kit (Abnova, Walnut, CA.). Triglycerides (Cayman Chemical Company, Ann Arbor, MI) and cell proliferation using the 3-(4,5-Dime-
thylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay (R&D Systems, Minneapolis, MN) were quantified using a colorimetric
enzymatic method with commercially available kits. For measurement of bile acids, mediumwas collected and reaction with 3 alpha-
hydroxysteroid dehydrogenase was measured by fluorescence intensity using the Bile Acid Assay Kit (Sigma-Aldrich, St Louis, MO)
according to the manufacturer’s instructions. We measured CYP3A4 activity using P450-Glo CYP3A4 Assay (Luciferin-IPA) (Prom-
ega Corporation, Madison, WI, USA, Cat# V9001) according to the manufacturer’s instructions. Cells were exposed to 20 uM of
Rifampicin (Sigma-Aldrich, Saint Louis, Missouri) for 48 hours to induce CYP3A4. Cryopreserved human fetal hepatocytes (gesta-
tional age: week 24/21) and adult hepatocytes were used as controls.
To test cholangiocytes bile acid transport, differentiating human iPS-Chol were harvest and cultured as 3D culture format, shortly
2x104 cells (the end of Stage 4 of cholangiocytes differentiation), were re-plated in a thick layer of Matrigel Basement Membrane
Matrix (Corning, New York, NY). Cells were then further differentiated intomature cholangiocytes usingmaturationmedium (Stage 5).
The functional analysis of human iPS-Chol was performed by measuring Cholyl-lysyl-fluorescein (CLF) transports, as described by
Sampaziotis et al. (2015). Briefly, the organoids were incubated with 5 mM of CLF (Corning Incorporated) for 30 min at 37C and then
washed with Leibovitz’s medium (Life Technologies). As a control, the same procedure was done using 5 mM of unconjugated fluo-
rescein isothiocyanate (FITC, Sigma-Aldrich). The imagens were collected after the incubation (loading phase) and 10 minutes after
(export phase). The measurements were made normalizing the fluorescence by the background and using the loading phase as 1.
To test endothelial cell function, human neonatal microvascular endothelial cells (Lonza, Walkersville, MD) or human iPSC-VECs
(iCell Endothelial Cells) (Cellular Dynamics, Fujifilm, Madison, WI) in culture (2D) and assembled vasculature of liver scaffolds were
incubated in EBM PLUS Basal Medium supplemented with EGM-2 SingleQuots Kit (Lonza, Walkersville, MD) for human neonatal
microvascular endothelial cells and VascuLife VEGF Medium (Cell Technologies, Fremont, CA) supplemented with iCell Endothelial
CellsMediumSupplement (Cellular Dynamics, Fujifilm,Madison,WI) for human iPS-derived endothelial cells containing either 1pMof
1a,25-dihydroxyvitamin D3 (Sigma-Aldrich, Saint Louis, MO) or 1 mM retinoic acid (Sigma-Aldrich, Saint Louis, MO) or 1mMSp-8-Br-
cAMPs (BIOLOG, Life Science Institute, Bremen, Germany), 1 mM or 100nM Phorbol myristate acetate (PMA) (Sigma-Aldrich, Saint
Louis, MO) and a combination of 100nM PMA/10 mMForskolin (Sigma-Aldrich, Saint Louis, MO) for 24 h. Human tissue plasminogen
activator was measured using an ELISA, according to the manufacturer’s instructions (Abcam, Cambridge, MA). Subsequently,
assembled vasculature of liver scaffolds was cultured in the liver culture system for 24 h. Next, 10 mg/ml FITC labeled acLDL (Invi-
trogen, Carlsbad, CA) was added to the perfused culture medium and recirculated for 24 h. Assembled liver scaffolds were washed
with fresh medium and liver lobes were dissected and prepared for imaging. Images were captured with a Nikon Eclipse Ti micro-
scope. All experiments were performed using either human neonatal microvascular endothelial cells (Lonza, Walkersville, MD) or hu-
man iPSC-VECs (iCell Endothelial Cells) (Cellular Dynamics, Fujifilm, Madison, WI) at passage 1-5.
Immunofluorescence
Human adult or fetal livers, engineered liver grafts or transplanted engineered liver grafts were fixed in 4% paraformaldehyde for 12 h
and 70% ethanol overnight at 4C, and then embedded in paraffin, cut sections (5-7 mm) were mounted on glass slides, for fluores-
cence staining. Antibodies specific for antigenswere acquired for immunofluorescence and list of the antibodies used can be found in
Key Resources Table. Slides were deparaffinized and hydrated, washed by PBS and blocked 1h with 10% donkey/goat serum.
Antigen retrieval was used, sections were then incubated with primary antibody overnight 4 C and secondary antibody 1h room tem-
perature, sections were covered with mounting media with 40,6-diamidino-2-phenylindole dihydrochloride (DAPI). For immunohisto-
chemistry staining, sections, were deparaffinized and processed for staining with hematoxylin and eosin. All procedures followed the
kit instructions. Images were captured with a Nikon Eclipse Ti microscope.
Auxiliary liver graft transplantation
All transplanted animals were pre-conditioned with retrorsine, animals were given two injections of retrorsine (Sigma-Aldrich, Saint
Louis, MO), 30mg/kg each, intraperitoneally, 2 weeks apart. Four weeks after the second injection, auxiliary liver transplantation was
performed. The auxiliary partial liver transplantation in the rat has been described in detail previously (Matsubara et al., 2015). Briefly,
after laparotomy and preparation of the infra-hepatic inferior vena cava (IHIVC), the right renal artery and vein were ligated and right
nephrectomy was performed to create the space of heterotopic liver transplantation. After proximal and distal clamping of the IHIVC,
the anterior wall of the IHIVC was cut as close to the ligated right renal vein as possible, for the anastomosis with the liver graft by an
end-to-side anastomosis using a continuous suture with 10-0 nylon (AROSurgical Instruments corporation, Newport Beach, CA).
Next, after clamping the recipient’s portal vein (PV), the splenic vein and the superior mesenteric vein (SMV), the PV was cut and
end-to-side anastomosis was performed between the graft PV and recipient’s PV. After finishing both anastomoses, PV was de-
clamped and the graft was re-perfused. Following reperfusion, PV was partially ligated between the pyloric vein and the PV anasto-
mosis. The stented bile duct of the graft was inserted into the duodenum after applying the purse-string suture and fixed to the
duodenal wall by tightening the suture. Finally, left lateral lobe of the rat liver was resected for induction of liver regenerative stimulus.
All transplanted animals were administrated FK506 (Astellas pharma, Tokyo, Japan) at 1 mg/kg/day to control any rejection episode
for the duration of the experiments.e11 Cell Reports 31, 107711, June 2, 2020
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Data from at least three sets of samples were used for statistical analysis. The statistical software JMP 10J version (SAS Institute,
Cary, NC, USA) was used for all analyses. All experiments were independently performed three times in triplicate. Due to the relatively
small sample size, normality testing was not feasible. Data are expressed as mean ± standard deviation (SD) and were compared
using an analysis of the Wilcoxon test. Values of p < 0.05 were considered statistically significant.Cell Reports 31, 107711, June 2, 2020 e12
